Vascular surgery company CryoLife Inc (NYSE:CRY) stated on Tuesday that it recorded a net loss of USD297,000 (USD0.01 per fully diluted common share) for the first quarter ended 31 March 2019.

This marks a rise in earnings when compared with a higher net loss of USD3.9m (USD0.11 per fully diluted common share) for the first quarter of 2018.

Total revenues of USD67.5m were generated for the first quarter of 2019, reflecting growth of 9%, and 11% on a non-GAAP constant currency basis, over USD62m in the first quarter of 2018. The increase was driven by strong revenue growth from JOTEC, On-X and BioGlue.

For 2019, the company expects total revenues in the range of USD280m to USD284m as well as non-GAAP earnings per share in the USD0.28 and USD0.32 range.